BioCentury
ARTICLE | Clinical News

Eylea aflibercept ophthalmic solution regulatory update

November 9, 2015 8:00 AM UTC

The European Commission approved Eylea aflibercept from Bayer to treat visual impairment due to myopic choroidal neovascularization (CNV). Eylea is approved in the EU to treat wet age-related macular ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article